Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aciclovir for HSV-2 Meningitis (AMEN)
2024-520042-31-00Phase 4Authorised
- Sponsor
- Aalborg University Hospital
- Start
- Jan 2025
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in Herpes simplex virus type 2 meningitis comparing Aciclovir/valaciclovir strategy with Placebo strategy (2 arms). Primary endpoint: Proportion of patients with TMS >6 at 7 days. Planned start Jan 2025; status: authorised.
02
Drugs
aciclovirvalaciclovir
03
Conditions
Herpes simplex virus type 2 meningitis
Beyond the preview
Go deeper on 2024-520042-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520042-31-00.